Skip to main content
Premium Trial:

Request an Annual Quote

Evotec Q4 Revenues Up 23 Percent Over Last Year

NEW YORK, Feb. 3 (GenomeWeb News) - Evotec OAI's fourth-quarter 2004 revenue jumped 23 percent over the same period in 2003, according to unaudited figures the Germany-based company released today.


The company reported preliminary revenue of €25.3 million ($32.8 million) for the quarter ended Dec. 31, 2004, compared to €20.5 million for the same quarter during the previous year.


However, revenue for the entire year fell to €72.7 million from €77.2 million one year ago. In a statement, Evotec blamed some of the decrease on cost control policies by pharmaceutical companies, soft financial markets, the weak US dollar, and the strong British pound.


Earnings before interest, taxes, depreciation, and amortization for the fourth quarter swelled to €2.6 million from €600,000 for the same quarter in 2003.


As of Dec. 31, the company reported cash and marketable securities of €15.3 million and receivables of €16.3 million, which Evotec expects to reduce to historical average and convert into cash in early 2005.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.